Evidence map›Paper›PMID 39081289›Full record

ArticleiScience2024

Case-control study on post-COVID-19 conditions reveals severe acute infection and chronic pulmonary disease as potential risk factors.

Pritha Ghosh, Michiel J M Niesen, Colin Pawlowski, Hari Bandi, Unice Yoo, Patrick J Lenehan, Praveen Kumar-M, Mihika Nadig, Jason Ross, Sankar Ardhanari and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Pritha Ghoshnference Labs, Bengaluru, India.
Michiel J M Niesennference, Inc., Cambridge, MA 02139, USA.
Colin Pawlowskinference, Inc., Cambridge, MA 02139, USA.
Hari Bandinference, Inc., Cambridge, MA 02139, USA.
Unice Yoonference, Inc., Cambridge, MA 02139, USA.
Patrick J Lenehannference, Inc., Cambridge, MA 02139, USA.
Praveen Kumar-Mnference Labs, Bengaluru, India.
Mihika Nadignference, Inc., Cambridge, MA 02139, USA.
Jason Rossnference, Inc., 18 3rd St. S.W., Rochester, MN 55902, USA.
Sankar Ardhanarinference, Inc., 2424 Erwin Road, Durham, NC 27705, USA.
John C O'HoroMayo Clinic, Rochester, MN, USA.
A J Venkatakrishnannference, Inc., Cambridge, MA 02139, USA.
Clifford J RosenMaine Medical Center, Portland, ME 04102, USA.
Amalio TelentiVir Biotechnology, Inc., San Francisco, CA, USA.
Ryan T HurtMayo Clinic, Rochester, MN, USA.
Venky Soundararajannference Labs, Bengaluru, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-COVID-19 conditions (long COVID) has impacted many individuals, yet risk factors for this condition are poorly understood. This retrospective analysis of 88,943 COVID-19 patients at a multi-state US health system compares phenotypes, laboratory tests, medication orders, and outcomes for 1,086 long-COVID patients and their matched controls. We found that history of chronic pulmonary disease (CPD) (odds ratio: 1.9, 95% CI: [1.5, 2.6]), migraine (OR: 2.2, [1.6, 3.1]), and fibromyalgia (OR: 2.3, [1.3, 3.8]) were more common for long-COVID patients. During the acute infection phase long COVID patients exhibited high triglycerides, low HDL cholesterol, and a high neutrophil-lymphocyte ratio; and were more likely hospitalized (5% vs. 1%). Our findings suggest severity of acute infection and history of CPD, migraine, chronic fatigue syndrome (CFS), or fibromyalgia as risk factors for long COVID. These results suggest that suppressing acute disease severity proactively, especially in patients at high risk, can reduce incidence of long COVID.

Indexed as

ImmunologyPublic healthRespiratory medicine

Identifiers

PMID39081289
PMCPMC11284568

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.